Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
Two epidemics, fueled by stigma and allowed to flourish amidst political neglect, set the course of Dr. Judith Feinberg’s professional life. So when she was asked […]
Advocates hail South Africa bedaquiline recommendation, replacing toxic injection for patients with drug-resistant tuberculosis
Medicine represents third choice over “deaf or dead” for many patients, health worker/tuberculosis survivor-founded organization says Praising the treatment policy decision of South Africa health officials […]
Tools to diagnose and monitor HIV, hepatitis B and C, and tuberculosis, as well as resistance to first-line TB treatment are among the tests included in […]
Brushing aside White House proposals to cut global HIV and other international disease response funding, members of the House Appropriations Labor, Health and Human Services, Education […]